Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 10/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 10/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | CCR4 | P51679 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20452263 | 1.00 | CCR6 (0.60) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL9978133 | 0.89 | CCR6 (0.58) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL20452168 | 0.87 | CXCR2 (0.61) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL9978025 | 0.87 | CXCR2 (0.61) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL9978132 | 0.87 | CCR6 (0.59) | CCR6CXCR2CXCR1 | |
| SCHEMBL20464592 | 0.83 | CCR6 (0.51) | CCR6CXCR2CXCR1 | |
| SCHEMBL30515691 | 0.83 | CCR6 (0.66) | CCR6CXCR2CXCR1 | |
| SCHEMBL9978020 | 0.83 | CCR6 (0.66) | CCR6CXCR2CXCR1 | |
| SCHEMBL20452209 | 0.83 | CCR6 (0.66) | CCR6CXCR2CXCR1 | |
| SCHEMBL9977969 | 0.81 | CXCR2 (0.56) | CCR6CXCR2CXCR1CXCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3681861-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | Ardea Biosciences, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | SYNTRIX BIOSYSTEMS INC. (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2019055509-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| WO-2017156270-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-2651932-B1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-8648070-B2 | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648070-B2 | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2012080457-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CCR6 20/4885CXCR2 2/4885CXCR1 1/4885 |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | CXCR1, CXCR2, CXCR6 | CCR6 20/4885CXCR2 2/4885CXCR1 1/4885 |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, SULT2A1 | CCR6 51/4885CXCR2 1/4885CXCR1 6/4885 |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | CXCR1, CXCR2, FPR2 | CCR6 30/4885CXCR2 2/4885CXCR1 1/4885 |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | CCR6 19/4885CXCR2 2/4885CXCR1 1/4885 |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | CXCR1, CXCR2, CXCR5 | CCR6 19/4885CXCR2 2/4885CXCR1 1/4885 |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CCR6 20/4885CXCR2 2/4885CXCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.